Business
EDAP, Telix explore PSMA PET and HIFU collaboration
EDAP TMS and Telix Pharmaceuticals signed a letter of intent to explore clinical research combining Focal One Robotic HIFU with Telix PSMA PET imaging agents in prostate cancer care.
Company
Telix Pharmaceuticals
Clinical
Telix doses first patient in phase 3 glioblastoma trial
The IPAX BrIGHT trial is evaluating TLX101-Tx with lomustine versus lomustine alone in patients with recurrent glioblastoma.
Business
Regeneron enters radiopharma through $2.1B Telix deal
The companies will co-develop and co-commercialize next-generation radiopharmaceutical therapies, with Telix receiving $40M upfront and eligibility for up to $2.1B in milestones.
Business
Telix, Regeneron enter $2.1B radiopharma partnership
The companies will co-develop radiopharmaceutical therapies and radiodiagnostics across multiple solid tumor targets.
Clinical
Telix glioma PET agent moves toward FDA decision
The FDA assigned a September 11, 2026, PDUFA goal date for Pixclara, an investigational F-18 FET PET agent for glioma imaging.